The immediate reaction on Wall Street to last month’s U.S. Supreme Court ruling upholding President Obama’s health care law was to buy hospital stocks and dump health insurance stocks. But at least one analyst expects the long-term outcome to be the exact opposite.
Eli Lilly and Co. got a boost of confidence last week that its project to launch the first effective Alzheimer’s treatment is on the right track—though it still faces hugely long odds.
Indiana University says an accrediting agency has approved its request to begin the accreditation process for the Schools of Public Health proposed for its Bloomington and Indianapolis campuses.
The buying spree is back on at WellPoint Inc., with a twist. A decade ago, the insurer consolidated Blue Cross and Blue Shield plans that catered to employers. Today, it is making deals to grow the non-employer part of its business.
WellPoint Inc. said it will pay for DNA testing for three children to see if they have an inherited heart disease their father suffers from that often strikes without warning, reversing an earlier decision to deny coverage.
Eli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking the drug to those taking a placebo.
Johnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available drug designed to target a cause of Alzheimer’s, rather than just its symptoms. Analysts say the potential drugs are long shots.
A chain of dental offices that abruptly closed multiple Indiana locations in December 2010 left patients without care, refunds or records, according to a complaint filed by the Office of the Indiana Attorney General.
Indiana University Health, as well as a partnership of Franciscan Alliance and American Health Network, have formed accountable care organizations that won the blessing of the federal Medicare Shared Savings program.
With spending running well ahead of revenue, West Lafayette-based Bioanalytical Systems Inc. ousts its CEO in favor of its CFO.
Investors and analysts like the fact that WellPoint is playing more aggressively in government-sponsored health plans, such as Medicaid and Medicare, which are projected to be the key sectors for growth for the next several years.
The Indianapolis health insurer is buying Virginia-based Amerigroup Corp. to expand in managed care for poor and elderly patients in the Medicare and Medicaid programs.
Eli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta, its biggest selling drug. The extension could mean more than a billion dollars in sales for the Indianapolis drug maker.
Erbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with advanced stomach tumors in a late-stage clinical trial.
Have employees reached the tipping point where rising health care costs have forced them to think seriously about jumping ship?
As medical innovation continues to flourish in our city … you can expect to see a direct impact on the where and how you and your loved ones receive comprehensive medical services.
When Helene Cross arrived to lead Fairbanks Addiction Treatment Center in 2001, the alcohol and drug rehabilitation hospital was as sick financially as its patients were physically.
The great results Regenstrief Institute has produced over the years in studies at Indianapolis’ Wishard Memorial Hospital have not held up when conducted in a wider variety of settings.
Bristol-Myers Squibb Co. has agreed to pay $5.3 billion to acquire former Eli Lilly and Co. partner Amylin Pharmaceuticals Inc., a maker of diabetes therapies. The deal is valued at about $7 billion, which includes Amylin’s debt and a payment to Eli Lilly and Co. of about $1.7 billion.
The U.S. Supreme Court’s ruling to uphold the Patient Protection & Affordable Care Act cleared a big cloud of uncertainty for employers, but with just 18 months before the most significant provisions of the law kick in, many questions remain. Three benefits consultants from Indianapolis-based Gregory & Appel Insurance—Bob Miller, Mike Miles and Karl Ahlrichs—sat down to discuss what the future looks like for employer health benefits.
